Seres Therapeutics Inc
MCRB14.185USD
+0.195+1.39%
Market hours （ET）Quotes delayed by 15 min
6.19MMarket Cap
0.08P/E TTM
More Details of Seres Therapeutics Inc Company
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Company Info
Ticker SymbolMCRB
Company nameSeres Therapeutics Inc
IPO dateJun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
Number of employees103
Security typeOrdinary Share
Fiscal year-endJun 26
Address101 Cambridge Park Drive
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02140
Phone16179459626
Websitehttps://www.serestherapeutics.com/
Ticker SymbolMCRB
IPO dateJun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
FY2023
FY2022
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
126.33M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Shareholders
Shareholders
Proportion
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.23%
Venture Capital
13.24%
Corporation
12.47%
Investment Advisor/Hedge Fund
1.46%
Research Firm
1.04%
Individual Investor
0.59%
Hedge Fund
0.45%
Bank and Trust
0.05%
Other
51.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
284
4.24M
48.53%
-1.00M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
2023Q1
378
115.00M
93.33%
-29.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Flagship Ventures
1.16M
13.24%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.09M
12.51%
+2.16K
+0.20%
Mar 31, 2025
Nestle SA
1.09M
12.47%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
304.60K
3.49%
+10.91K
+3.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
84.10K
0.96%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
80.94K
0.93%
+5.42K
+7.17%
Mar 31, 2025
Bank Vontobel AG
54.30K
0.62%
+7.38K
+15.74%
Mar 31, 2025
UBS Financial Services, Inc.
69.22K
0.79%
+52.11K
+304.43%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
41.70K
0.48%
-1.59K
-3.66%
Mar 31, 2025
Susquehanna International Group, LLP
35.86K
0.41%
+19.47K
+118.77%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Growth ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
